Impact of nelfinavir (given at 1250mg bid as part of a combination antiretroviral regimen) on area under the curve for rifabutin and 25-O-desacetyl rifabutin when rifabutin is given 300 mg bi-weekly as part of tuberculosis chemotherapy. [clinicaltrials_resource:f4e1ab4f2f1e9a2f08449948eecec2f7]
(Click here for more information about the Tuberculosis Trials Consortium(TBTC)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Impact of nelfinavir (given at 1250mg bid as part of a combination antiretroviral regimen) on area under the curve for rifabutin and 25-O-desacetyl rifabutin when rifabutin is given 300 mg bi-weekly as part of tuberculosis chemotherapy. [clinicaltrials_resource:f4e1ab4f2f1e9a2f08449948eecec2f7]
(Click here for more information about the Tuberculosis Trials Consortium(TBTC)
Bio2RDF identifier
f4e1ab4f2f1e9a2f08449948eecec2f7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f4e1ab4f2f1e9a2f08449948eecec2f7
measure [clinicaltrials_vocabulary:measure]
Impact of nelfinavir (given at ...... of tuberculosis chemotherapy.
description
(Click here for more information about the Tuberculosis Trials Consortium(TBTC)
identifier
clinicaltrials_resource:f4e1ab4f2f1e9a2f08449948eecec2f7
title
Impact of nelfinavir (given at ...... of tuberculosis chemotherapy.
@en
type
label
Impact of nelfinavir (given at ...... 1ab4f2f1e9a2f08449948eecec2f7]
@en